This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
zacks-consensus-estimate: Archive
Wall Street Analysts Believe McGraw Hill, Inc. (MH) Could Rally 48.6%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for McGraw Hill, Inc. (MH) points to a 48.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MHNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does LiveOne (LVO) Have the Potential to Rally 122.87% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 122.9% upside potential for LiveOne (LVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LVOPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Kontoor (KTB) Could Surge 27.03%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 27% upside potential for Kontoor (KTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KTBNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Starz Entertainment Corp. (STRZ) Climb 29.98% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 30% upside potential for Starz Entertainment Corp. (STRZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
STRZPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Cheniere Energy (LNG) Boasts Earnings & Price Momentum: Should You Buy?
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
LNGPositive Net Change
earnings-estimates growth-investing zacks-consensus-estimate zacks-rank
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
by Zacks Equity Research
Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +1.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
XGNPositive Net Change TSNDFPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Core Molding Technologies (CMT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Core Molding Technologies (CMT) delivered earnings and revenue surprises of +56.52% and +12.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
CMTNegative Net Change CNMNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Stagwell (STGW) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Stagwell (STGW) delivered earnings and revenue surprises of +5.26% and +2.65%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
STGWPositive Net Change HYFTNo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +87.50% and +20.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ADCTNegative Net Change GYRENegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -31.21% and +47.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
IRDNegative Net Change PRQRNo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank